REG - Poolbeg Pharma PLC - Poolbeg Partners with a Nasdaq-Listed Biopharma

Poolbeg PharmaAnnouncement

17/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231017:nRSQ2985Qa&default-theme=true

RNS Number : 2985Q  Poolbeg Pharma PLC  17 October 2023

Poolbeg Pharma plc

 

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral
Delivery Platform

 

Strategic collaboration focussed on the development of an optimised drug for a
metabolic condition using Poolbeg's licensed oral delivery technology

 

Collaboration may expand to a full licensing agreement

 

17 October 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company targeting diseases with a high unmet medical need,
announces that it has signed a strategic collaboration agreement with a Nasdaq
listed biopharma company for the development of an optimised oral drug to
treat a metabolic condition.

 

Under the agreement, the Company will receive funding to work with its new
partner to produce a prototype drug utilising Poolbeg's licensed oral delivery
technology*. Poolbeg believes that this technology can help to optimise the
delivery of its partner's novel drug to its ideal site of therapeutic action.

 

The Company is optimistic that this strategic collaboration can progress to a
full licensing agreement in time, whereby the Nasdaq listed biopharma could
integrate this novel oral delivery technology into its pipeline.

 

This marks another significant milestone in Poolbeg's journey towards early
revenues and underscores the Company's commitment to advancing treatments for
metabolic conditions.

 

* Poolbeg has an exclusive licence to patented oral delivery technologies for
all metabolic conditions and is utilising the same technology for its Oral
GLP-1 agonist programme.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "Our
partner recognises the benefits of Poolbeg's licensed oral delivery technology
and we look forward to optimising the development of this innovative drug for
patients in an area where there is a clear unmet need. We are optimistic that
this strategic collaboration has the potential to progress to a full licensing
agreement."

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                    +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                  +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                               +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                      +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg
Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
Pharma also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, leading to faster development and greater
commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg Pharma's
existing pipeline, the Company is progressing programmes in oncology and
metabolic syndromes; adding disease areas with significant addressable
markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/) , an industry
leading infectious disease and human challenge trials business, Poolbeg Pharma
has access to knowledge, experience, and clinical data from over 20 years of
human challenge trials. The Company is using these insights to acquire new
assets as well as reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction in p38
MAP kinase driven cytokines in a clinical setting; a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is progressing two Artificial Intelligence (AI) Programmes to add
promising new assets to its pipeline as well as developing an Oral Vaccine
Programme and utilising its licensed Oral Delivery Platform to target
metabolic conditions.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/) @PoolbegPharma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIBDGGSBDGXL